“Women are fully capable of making difficult decisions, but meaningful choice requires trusted, vetted information,” writes Michelle Sie Whitten of the Global Down Syndrome Foundation.
Vetenskapsnyheter
The Tarasoff case remains a pivotal marker in bioethics at the bicentennial as we now reach the country’s 250th birthday.
Methadone for opioid addiction has been available only at specialty clinics. A bipartisan bill would greatly expand access.
Eli Lilly is investing in a small startup developing a medication to spur hair growth, and potentially also treat endometriosis.
People are getting more care and using lots of GLP-1 drugs, fueling a sharp increase in health care spending.
A judge temporarily blocked federal prosecutors in Texas from getting access to the medical records of transgender patients treated at New York hospitals on Wednesday.
A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central Africa, is set to begin next week, WHO officials said.
In this edition of STAT's AI Prognosis: Brittany Trang brings the latest from BIO on how biotech companies are approaching artificial intelligence.
A new study published in Nature uses artificial intelligence to identify people at high risk for sudden cardiac death, and pinpoints a possible reason.
RIP Sangamo, onshoring with drug manufacturing, and more biotech news from The Readout
Regenxbio plans to apply for accelerated approval for its gene therapy for Duchenne muscular dystrophy.
Regenxbio plans to submit its Duchenne gene therapy for FDA approval, just a month after it said that regulators wanted to see another trial.
Government can't restrict SNAP dollars on candy, diminishing returns for IVF add-ons, and other health news
A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
“With the right structure, Americans will roll up their sleeves, do the science, and trust the result,” Manoush Zomorodi writes.
An abandoned heart-failure trial offers a rare window into devices that the FDA deems "breakthrough" but never reach patients.
Scientists can’t ignore the ethical complexities of new embryo editing advances.
The FDA told wearable maker Whoop last week that it would not take further enforcement action over the company's blood pressure feature.
STAT+: Want high-quality generic drugs? One expert has ideas on how consumers can trust their supply
Can the quality of generic drugs in the U.S. be made more consistent? One expert has some ideas on how to do it.
The federal government can't block benefits from the nation's largest food aid program from being used to buy candy, soda, and other sugary drinks, a judge ruled.
The Justice Department has charged a Texas doctor in an $89 million health care fraud scheme, accusing him of billing insurers for medically unnecessary cardiovascular screening tests.
Giving an individual special access to an experimental obesity drug is highly unusual.
The latest pharmaceutical news from the Pharmalot campus via the Pharmalittle newsletter
The "triple-G" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout
In this edition of STAT Health Tech: OpenEvidence adds AI to detect heart disease, and Cadence raises $100 million, and more.